EHDP en es it fr

EHDP Brand names, EHDP Analogs

EHDP Brand Names Mixture

  • No information avaliable

EHDP Chemical_Formula


EHDP RX_link

EHDP fda sheet

EHDP msds (material safety sheet)

EHDP Synthesis Reference

No information avaliable

EHDP Molecular Weight

391.46 g/mol

EHDP Melting Point

No information avaliable

EHDP H2O Solubility

10 mg/L

EHDP State




EHDP Dosage Forms

Tablets (100 mg)

EHDP Indication

For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

EHDP Pharmacology

Flavoxate is a spasmolytic flavone derivative that acts by relaxing the smooth muscle in the urinary tract. Flavoxate is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Muscarinic receptors play an important role in several major cholin-ergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.

EHDP Absorption

Well absorbed from gastrointestinal tract.

EHDP side effects and Toxicity

The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.

EHDP Patient Information

EHDP Organisms Affected

Humans and other mammals